Cytokines induced during influenza virus infection

Current Pharmaceutical Design

Volumn 23, Issue 18, 2017, Pages 2616-2622

  Betáková, Tatiana ^a,b   Kostrábová, Anna ^b   Lachová, Veronika ^a   Turianová, Lucia ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

^b Physics and Informatics   (Slovakia)

Author keywords

B cell; Chemokines; Cytokines; Immunity; Influenza virus; Interferon; Interleukin; Macrophage; NK cell; Pathogenesis; T cell

Indexed keywords

CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; BIOLOGICAL MARKER;

ADAPTIVE IMMUNITY; AVIAN INFLUENZA VIRUS; BACTERIAL INFECTION; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS VIRULENCE; ANIMAL; BLOOD; IMMUNOLOGY; INFLUENZA A VIRUS; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY; VIRUS REPLICATION;

ANIMALS; BIOMARKERS; CYTOKINES; HUMANS; IMMUNITY, INNATE; INFLUENZA A VIRUS; INFLUENZA, HUMAN; VIRUS REPLICATION;

EID: 85025145447     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170316123736     Document Type: Review

References (84)

1. Fauci AS. Seasonal and pandemic influenza preparedness: science and countermeasures. J Infect Dis 2006; 194: S73-6.
2. Marion T, Elbahesh H, Thomas PG et al. Respiratory Mucosal Proteome Quantification in Human Influenza Infections. PLoS One 2016; 11(4): e0153674.
3. McClain MT, Henao R, Williams J et al. Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge. Clin Exp Immunol 2016; 183: 441-51.
4. Kell AM, Gale M Jr. RIG-I in RNA virus recognition. Virology 2015; 479-480: 110-21.
5. Kawai T, Takahashi K, Sato S et al. IPS-1, an adaptor triggering RIG-I-and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6: 981-8.
6. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005; 19: 727-40.
7. Takahashi K, Kawai T, Kumar H, Sato S, Yonehara S, Akira S. Roles of caspase-8 and caspase-10 in innate immune responses to double-stranded RNA. J Immunol 2006; 176: 4520-4.
8. Chiang JJ, Davis ME, Gack MU. Regulation of RIG-I-like receptor signaling by host and viral proteins. Cytokine Growth Factor Rev 2014; 25: 491-505.
9. Kuiken T, Riteau B, Fouchier RA, Rimmelzwaan GF. Pathogenesis of influenza virus infections: the good, the bad and the ugly. Curr Opin Virol 2012; 2: 276-86.
10. Kumar Y, Liang C, Limmon GV, et al. Molecular analysis of serum and bronchoalveolar lavage in a mouse model of influenza reveals markers of disease severity that can be clinically useful in humans. PLoS One 2014; 9: e86912.
11. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012; 76: 16-32.
12. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular Immmnology 8th ed. Elsevier, 2015.
13. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995; 182: 1301-14.
14. Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-21.
15. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 2002; 14: 129-35.
16. Egesten A, Eliasson M, Johansson HM, et al. The CXC chemokine MIG/CXCL9 is important in innate immunity against Streptococcus pyogenes. J Infect Dis 2007; 195: 684-93.
17. Davey RT Jr., Lynfield R, Dwyer DE, et al. The association between serum biomarkers and disease outcome in influenza A (H1N1)pdm09 virus infection: results of two international observational cohort studies. PLoS One 2013; 8: e57121.
18. Bradley-Stewart A, Jolly L, Adamson W, et al. Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09. J Clin Virol 2013; 58: 100-7.
19. Sun G, Ota C, Kitaoka S, et al. Elevated serum levels of neutrophil elastase in patients with influenza virus-associated encephalopathy. J Neurol Sci 2015; 349: 190-5.
20. Oshansky CM, Gartland AJ, Wong SS, et al. Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load. Am J Respir Crit Care Med 2014; 189: 449-62.
21. Lee N, Wong CK, Chan PK, et al. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS One 2011; 6: e26050.
22. Yang ZF, Mok CK, Liu XQ, et al. Clinical, virological and immunological features from patients infected with re-emergent avianorigin human H7N9 influenza disease of varying severity in Guangdong province. PLoS One 2015; 10: e0117846.
23. Chi Y, Zhu Y, Wen T, et al. Cytokine and chemokine levels in patients infected with the novel avian influenza A (H7N9) virus in China. J Infect Dis 2013; 208: 1962-7.
24. Marion T, Elbahesh H, Thomas PG, DeVincenzo JP, Webby R, Schughart K. Respiratory Mucosal Proteome Quantification in Human Influenza Infections. PLoS One 2016; 11: e0153674.
25. Crowley JJ, Zhabotynsky V, Sun W, et al. Analyses of allelespecific gene expression in highly divergent mouse crosses identifies pervasive allelic imbalance. Nat Genet 2015; 47: 353-60.
26. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-54.
27. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19: 568-74.
28. Cruikshank WW, Long A, Tarpy RE, et al. Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol 1995; 13: 738-47.
29. Deng A, Chen S, Li Q, Lyu SC, Clayberger C, Krensky AM. Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator. J Immunol 2005; 174: 5243-8.
30. Wang Z, Zhang A, Wan Y, et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA 2014; 111: 769-74.
31. Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363: 617-9.
32. Chan MC, Cheung CY, Chui WH, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005; 6: 135.
33. Walsh KB, Teijaro JR, Rosen H, Oldstone MB. Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. Immunol Res 2011; 51: 15-25.
34. Monteerarat Y, Sakabe S, Ngamurulert S, et al. Induction of TNFalpha in human macrophages by avian and human influenza viruses. Arch Virol 2010; 155: 1273-9.
35. Aoyagi T, Newstead MW, Zeng X, Kunkel SL, Kaku M, Standiford TJ. IL-36 receptor deletion attenuates lung injury and decreases mortality in murine influenza pneumonia. Mucosal Immunol 2016. doi: 10.1038/mi.2016.107.
36. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003; 4: 69-77.
37. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30: 555-64.
38. Lin JD, Feng N, Sen A, Balan M, et al. Distinct roles of type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infections. PLoS Pathog 2016; 12: e1005600.
39. Uzé G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell 1990; 60: 225-34.
40. Cleary CM, Donnelly RJ, Soh J, Mariano TM, Pestka S. Knockout and reconstitution of a functional human type I interferon receptor complex. J Biol Chem 1994; 269: 18747-9.
41. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFNlambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017.
42. Cohen TS, Prince AS. Bacterial pathogens activate a common inflammatory pathway through IFNλ regulation of PDCD4. PLoS Pathog 2013; 9: e1003682.
43. Blazek K, Eames HL, Weiss M, et al. IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production. J Exp Med 2015; 212: 845-53.
44. Lukacikova L, Oveckova I, Betakova T, et al. Antiviral effect of interferon lambda against lymphocytic choriomeningitis Virus. J Interferon Cytokine Res 2015; 35: 540-53.
45. Mahlakõiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P. Leukocyte-derived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog 2015; 11, e1004782.
46. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749-58.
47. Bolen CR, Ding S, Robek MD, Kleinstein SH. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 2014; 59: 1262-72.
48. Jilg N, Lin W, Hong J, et al. Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 2014; 59: 1250-61.
49. Cohen TS, Parker D. Microbial pathogenesis and type III interferons. Cytokine Growth Factor Rev 2016; 29: 45-51.
50. Cohen TS, Parker D. Microbial pathogenesis and type III interferons. Cytokine Growth Factor Rev 2016; 29: 45-51.
51. Griffiths SJ, Koegl M, Boutell C, et al. A systematic analysis of host factors reveals a Med23-interferon-λ regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog. 2013; 9: e1003514.
52. Swider A, Siegel R, Eskdale J, Gallagher G. Regulation of interferon lambda-1 (IFNL1/IFN-λ1/IL-29) expression in human colon epithelial cells. Cytokine. 2014; 65: 17-23.
53. Svetlikova D, Kabat P, Ohradanova A, Pastorek J, Betakova T. Influenza A virus replication is inhibited in IFN-λ2 and IFN-λ3 transfected or stimulated cells. Antiviral Res 2010; 88: 329-33.
54. Pothlichet J, Meunier I, Davis BK, et al. Type I IFN triggers RIGI/ TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells. PLoS Pathog 2013; 9: e1003256.
55. Bennett AL, Smith DW, Cummins MJ, Jacoby PA, Cummins JM, Beilharz MW. Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respir Viruses 2013; 7: 854-62.
56. Svancarova P, Svetlikova D, Betakova T. Induction of interferon lambda in influenza A virus infected cells treated with shRNAs against M1 transcript. Acta Virol 2015; 59: 148-55.
57. Škorvanová L, Švančarová P, Svetlíková D, Betáková T. Protective efficacy of IFN-ω AND IFN-λs against influenza viruses in induced A549 cells. Acta Virol 2015; 59: 413-7.
58. Svancarova P, Svetlikova D, Betakova T. Synergic and antagonistic effect of small hairpin RNAs targeting the NS gene of the influenza A virus in cells and mice. Virus Res 2015; 195: 100-11.
59. Kim S, Kim MJ, Kim CH, et al. The Superiority of IFN-lambda as a Therapeutic Candidate to Control Acute Influenza Viral Lung Infection. Am J Respir Cell Mol Biol 2016 Sep 15.
60. Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice J Clin Invest 2009; 119: 1910-20.
61. Lee B, Robinson KM, McHugh KJ, et al. Influenza-induced type I interferon enhances susceptibility to gram-negative and grampositive bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol 2015; 309: L158-67.
62. S. Nakamura, K.M. Davis, J.N. Weiser Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest 2011; 121: 3657-65
63. Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol 2012; 86: 12304-12.
64. Robinson KM, Lee B, Scheller EV, et al. The role of IL-27 in susceptibility to post-influenza Staphylococcus aureus pneumonia. Respir Res 2015; 16: 10.
65. Pang IK, Pillai PS, Iwasaki A. Efficient influenza A virus replication in the respiratory tract requires signals from TLR7 and RIG-I. Proc Natl Acad Sci USA 2013; 110: 13910-5.
66. Planet PJ, Parker D, Cohen TS, et al. Interferon-lambda restructures the nasal microbiome and increases susceptibility to staphylococcus aureus superinfection. mBio 2016; 7: e01939-115.
67. van Boxel-Dezaire AH, Stark GR. Cell type-specific signaling in response to interferon-gamma Curr Top Microbiol Immunol 2007; 316: 119-54.
68. Igarashin K, Garotta G, Ozmen L, et al. Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. J Biol Chem 1994; 269: 14333-6.
69. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact Nat Rev Mol Cell Biol 2002; 3: 651-62.
70. Eilers A, Decker T. Activity of Stat family transcription factors is developmentally controlled in cells of the macrophage lineage. Immunobiology 1995; 193: 328-33.
71. Kotenko SV, Pestka S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 2000; 19: 2557-65.
72. Roff SR, Noon-Song EN, Yamamoto JK. The significance of interferon-γ in HIV-1 pathogenesis, therapy, and prophylaxis. Front Immunol 2014; 4: 498.
73. Baumgarth N, Kelso A. In vivo blockade of gamma interferon affects the influenza virus-induced humoral and the local cellular immune response in lung tissue. J Virol 1996; 70: 4411-8.
74. Graham MB, Dalton DK, Giltinan D, Braciale VL, Stewart TA, Braciale TJ. Response to influenza infection in mice with a targeted disruption in the interferon-γ gene. J Exp Med 1993; 178: 1725-32.
75. Ramana CV, DeBerge MP, Kumar A, Alia CS, Durbin JE, Enelow RI. Inflammatory impact of IFN-γ in CD8+ T cell-mediated lung injury is mediated by both Stat1-dependent and-independent pathways. Am J Physiol Lung Cell Mol Physiol 2015; 308: L650-7.
76. Prabhu N, Ho AW, Wong KH, et al. Gamma interferon regulates contraction of the influenza virus-specific CD8 T cell response and limits the size of the memory population. J Virol 2013; 87: 12510-22.
77. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008; 14: 558-4.
78. Gack MU, Albrecht RA, Urano T, et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by RIG-I. Cell Host Microbe 2009; 5: 439-449.
79. Lee J, Henningson J, Ma J, et al. Effects of PB1-F2 on the pathogenicity of H1N1 swine influenza virus in mice and pigs. J Gen Virol 2016 doi: 10.1099/jgv.0.000695.
80. Wang C, Lee HH, Yang ZF, Mok CK, Zhang Z. PB2-Q591K Mutation Determines the Pathogenicity of Avian H9N2 Influenza Viruses for Mammalian Species. PLoS One 2016; 11: e0162163.
81. Prokopyeva EA, Romanovskaya AA, Sharshov KA, et al. Pathogenicity assessment of wild-type and mouse-adapted influenza A(H1N1)pdm09 viruses in comparison with highly pathogenic influenza A(H5N1) virus. Histol Histopathol 2017 Jan 13: 11866. doi: 10.14670/HH-11-866.
82. Hu M, Yuan S, Zhang K, et al. PB2 substitutions V598T/I increase the virulence of H7N9 influenza A virus in mammals. Virology 2017; 501: 92-101.
83. Varga ZT, Ramos I, Hai R et al. The influenza virus protein PB1-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein. PLoS Pathog 2011; 7: e1002067.
84. Vidy A, Maisonnasse P, Da Costa B, et al. The influenza virus protein PB1-F2 increases viral pathogenesis through neutrophil recruitment and NK cells inhibition. PLoS One 2016; 11: e0165361.